التفاصيل البيبلوغرافية
العنوان:
PROPEL: A randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients
المؤلفون:
Propel, Investigators , Thommes, J , Najera, I , Chen, Yc , Munson, Ml , Ipe, D , Vierling, J , Pockros, P , Bzowej, N , Rodriguez Torres, M , Zeuzem, S , Mm, Ma , Ferenci, P , Herring, R , Jensen, D , Wedemeyer, H , Agarwal, K , Andreone, P , Benhamou, Y , Berg, T , Bloomer, J , Bronowicki, J , Brunetto, MAURIZIA ROSSANA , Bruno, S , Calleja, Jl , Iglesias, Ma , Cheng, W , Ciancio, A , Clark, V , Crawford, D , de Lédinghen, V , Desmond, P , Diago, M , Dikopoulos, N , Freilich, B , Godofsky, E , Hassanein, T , Hézode, C , Jacobson, I , Klass, Dm , Kuo, A , Lee, Ss , Leggett, B , Macdonald, Ga , Mac Quillan, G , Marotta, P , Vila, R , Pol, S , Ramji, A , Rasenack, Jw , Ratziu, V , Roberts, S , Romero Gómez, M , Rosenberg, W , Rossaro, L , Salmeron, Fj , Sánchez Tapias, Jm , Sanyal, Aj , Scuteri, A , Sepe, T , Sheikh, A , Sherman, M , Simon, Gl , Slim, J , Smith, Jp , Solà, R , Strasser, Si , Strohecker, J , Sulkowski, M , Tran, A , Willems, B , Yoshida, E , Zachoval, R , Zarski, J. .
سنة النشر:
2013
مصطلحات موضوعية:
Adult , Male , medicine.medical_specialty , Cirrhosis , Adolescent , Genotype , Hepatitis C virus , Hepacivirus , medicine.disease_cause , Placebo , Gastroenterology , Deoxycytidine , law.invention , Polyethylene Glycols , chemistry.chemical_compound , Young Adult , Randomized controlled trial , Double-Blind Method , law , Pegylated interferon , Internal medicine , Ribavirin , medicine , Humans , Aged , Hepatology , Dose-Response Relationship, Drug , business.industry , Interleukins , virus diseases , Interferon-alpha , Hepatitis C, Chronic , Middle Aged , medicine.disease , digestive system diseases , Recombinant Proteins , Surgery , Treatment Outcome , chemistry , RNA, Viral , Drug Therapy, Combination , Female , Interferons , business , Mericitabine , medicine.drug
الوصف:
Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C virus (HCV). Treatment-naive HCV genotype 1 or 4 patients were randomized to double-blind treatment with oral mericitabine at a dosage of 500 mg twice-daily (BID) for 12 weeks (A), 1,000 mg BID for 8 (B) or 12 weeks (C and D), or placebo BID for 12 weeks (E). All patients received pegylated interferon alpha-2a (Peg-IFNα-2a; 40 kD)/ribavirin (RBV) at standard doses for 24 or 48 weeks during and after mericitabine/placebo therapy. Patients in arms A-C who maintained a virologic response (VR) (HCV RNA
اللغة:
English
URL الوصول:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e520e34f9e35bb4e185dc082ad781d46 http://hdl.handle.net/2318/145343
حقوق:
CLOSED
رقم الأكسشن:
edsair.doi.dedup.....e520e34f9e35bb4e185dc082ad781d46
قاعدة البيانات:
OpenAIRE
